<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lymphoid interstitial pneumonia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lymphoid interstitial pneumonia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lymphoid interstitial pneumonia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Karen A Fagan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Talmadge E King, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kevin R Flaherty, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul Dieffenbach, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 21, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lymphoid interstitial pneumonia (LIP) is an uncommon form of interstitial lung disease in adults that is characterized histopathologically by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements [
         <a href="#rid1">
          1,2
         </a>
         ]. First described in 1966 by Carrington and Liebow [
         <a href="#rid3">
          3
         </a>
         ], LIP is one entity within a spectrum of lymphoproliferative disorders that can involve the lung. Many of the cases previously diagnosed as LIP are now considered cellular nonspecific interstitial pneumonia (NSIP) [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The etiology, clinical manifestations, diagnosis, and treatment of LIP will be reviewed here. The pathologic classification of the idiopathic interstitial pneumonias and an approach to the evaluation and diagnosis of interstitial lung disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4302.html" rel="external">
          "Idiopathic interstitial pneumonias: Classification and pathology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p>
         The American Thoracic Society (ATS) and European Respiratory Society (ERS) statement on the classification of idiopathic interstitial pneumonias, as well as other ATS guidelines, can be accessed through the ATS web site at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.thoracic.org%2Fstatements%2F&amp;token=Pby%2FnGkMB8TdW5V6epNUr3SRsNf6YBT3Fr3MIDgZvpZGvZXjM5qSgaeGcxqQwZtc&amp;TOPIC_ID=4361" target="_blank">
          www.thoracic.org/statements
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CLASSIFICATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lung is occasionally the primary organ of involvement in a variety of lymphoproliferative disorders [
         <a href="#rid5">
          5
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoid interstitial pneumonia (LIP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pseudolymphoma
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphomatoid granulomatosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Angioimmunoblastic T cell lymphoma (angioimmunoblastic lymphadenopathy)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary pulmonary lymphoma
        </p>
        <p>
        </p>
        <p>
         LIP represents a benign polyclonal proliferation (usually of mature B or T cells) that can either diffusely involve the lung or be a focal process. Focal LIP is probably the same entity as pseudolymphoma of the lung, given the very similar histology and clinical outcomes of the two disorders [
         <a href="#rid6">
          6
         </a>
         ]. Identification of the infiltrate as a monoclonal proliferation of lymphocytes implies a malignant population rather than LIP [
         <a href="#rid1">
          1,5
         </a>
         ]. Other features of LIP may include type II cell hyperplasia, occasional noncaseating granulomas, and germinal centers [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cause of lymphoid interstitial pneumonia (LIP) is unknown. It likely involves derangements in the immune system and/or manifestations of an underlying infection (especially viral).
        </p>
        <p>
         Among non-HIV-infected patients, the most common associated conditions are hypergammaglobulinemia, Sjögren's disease, other autoimmune conditions, and hypogammaglobulinemia with relative incidences of about 40, 30, 15, and 8 percent, respectively [
         <a href="#rid1">
          1,7-9
         </a>
         ]. Among HIV-infected adults, LIP was an uncommon complication prior to widespread use of antiretroviral therapy (ART); since then it has become even less frequent.
        </p>
        <p>
         In children, LIP is most frequently associated with perinatally acquired HIV, juvenile idiopathic arthritis, and a variety of inborn errors of immunity.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Idiopathic
         </span>
         <span class="headingEndMark">
          —
         </span>
         Less than 20 percent of cases of LIP have no clear underlying cause [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Rheumatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         LIP is associated with rheumatic diseases and processes associated with autoantibody production (especially those with dysproteinemias), including (among others) Sjögren's disease, rheumatoid arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, celiac sprue, myasthenia gravis, pernicious anemia, chronic active hepatitis, and biliary cirrhosis  (
         <a class="graphic graphic_table graphicRef70714" href="/z/d/graphic/70714.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid6">
          6,10,11
         </a>
         ].
        </p>
        <p>
         Sjögren's disease is associated with one-fourth of reported cases of LIP in adults, often with a marked monoclonal or polyclonal gammopathy. The pulmonary disease may precede or follow the diagnosis of the underlying process, whether it is Sjögren's disease or another rheumatic disease or dysproteinemia. (See
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Similarly, LIP may predate the diagnosis of other rheumatic diseases [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Immunodeficiency/dysregulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A form of lymphocytic interstitial pneumonitis, known as granulomatous and lymphocytic interstitial lung disease (GLILD), has been described in patients with common variable immunodeficiency (CVID) [
         <a href="#rid12">
          12
         </a>
         ]. The etiology of GLILD is not known, but may be related to human herpes virus type 8 (HHV8) infection. On histopathology, follicular bronchiolitis may accompany GLILD. (See
         <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">
          "Pulmonary complications of primary immunodeficiencies", section on 'Interstitial diseases'
         </a>
         .)
        </p>
        <p>
         In addition to CVID, GLILD has also been reported in patients with other immunodeficiencies, such as hypomorphic mutations in recombination-activating gene 1 (RAG1), haploinsufficiency of cytotoxic T lymphocyte antigen-4 (CTLA4), and deficiency in lipopolysaccharide responsive beige-like anchor protein (LRBA). LIP may also arise due to immune dysfunction caused by pathogenic variants in other genes, including
         <em>
          STAT3
         </em>
         and
         <em>
          GATA2
         </em>
         . (See
         <a class="medical medical_review" href="/z/d/html/6381.html" rel="external">
          "Classification of diffuse lung disease (interstitial lung disease) in infants and children", section on 'Lymphoid interstitial pneumonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Virus-associated
         </span>
         <span class="headingEndMark">
          —
         </span>
         LIP has been frequently associated with viruses that lead to or result from immune dysregulation. Most notably, LIP has a highly increased incidence in persons infected with HIV, especially among children [
         <a href="#rid13">
          13-15
         </a>
         ]. LIP occurs in 25 to 40 percent of children with untreated perinatally acquired HIV and usually presents in the second or third year of life. LIP is less common in adults with HIV infection, particularly in those treated with antiretroviral therapy. LIP can be seen in 27 to 59 percent of HIV-infected patients with diffuse infiltrative lymphocytosis syndrome (DILS), which usually presents with salivary gland enlargement and xerostomia [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">
          "Evaluation of pulmonary symptoms in persons with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5963.html" rel="external">
          "Pediatric HIV infection: Classification, clinical manifestations, and outcome"
         </a>
         .)
        </p>
        <p>
         Human T-lymphotropic virus type I (HTLV-I), a retrovirus, has also been implicated in LIP in Japanese patients [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8316.html" rel="external">
          "Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology"
         </a>
         .)
        </p>
        <p>
         Improvement of LIP with antiretroviral therapy alone has led some to theorize that either HIV viral replication itself may be driving the proliferation of immune cells or that HIV-related immunosuppression has allowed another virus, such as Epstein-Barr virus (EBV) to promote lymphocyte proliferation [
         <a href="#rid18">
          18,19
         </a>
         ]. In situ hybridization studies of biopsy specimens of patients with LIP (both with and without HIV) show a significant increase in the presence of EBV genome compared to other chronic lung disease specimens [
         <a href="#rid20">
          20
         </a>
         ]. Serologic evidence of recrudescent or primary EBV infection has been observed in children and adults with LIP [
         <a href="#rid21">
          21,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1024044985">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rare cases of LIP have been reported in patients with use of the medication diphenylhydantoin, benign hypergammaglobulinemic purpura of Waldenström, pulmonary amyloidosis, and surfactant protein C deficiency [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h1">
          PATHOLOGIC FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The histopathology of lymphoid interstitial pneumonia (LIP) is characterized by an interstitial infiltrate of lymphocytes, plasma cells, and histiocytes  (
         <a class="graphic graphic_table graphicRef69805" href="/z/d/graphic/69805.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid1">
          1,4,23
         </a>
         ]. Germinal centers and multinucleated giant cells with noncaseating granulomas may also be found  (
         <a class="graphic graphic_picture graphicRef63982 graphicRef75674 graphicRef52227" href="/z/d/graphic/63982.html" rel="external">
          picture 1A-C
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. According to the American Thoracic Society/European Respiratory Society (ATS/ERS) classification, the characteristic feature of LIP is extensive alveolar septal infiltration, although the cellular infiltrate may sometimes appear along bronchi and vessels  (
         <a class="graphic graphic_picture graphicRef53820" href="/z/d/graphic/53820.html" rel="external">
          picture 2
         </a>
         ). Thus, LIP is differentiated from diffuse lymphoid hyperplasia, which predominantly affects areas of the interstitium other than alveolar septa (eg, bronchovascular bundles and interlobular septa) [
         <a href="#rid4">
          4,24
         </a>
         ].
        </p>
        <p>
         The histopathology of granulomatous and lymphocytic interstitial lung disease (GLILD), a variant of LIP that may develop in patients with common variable immunodeficiency (CVID), often shows both peribronchiolar and diffuse interstitial infiltration, and &gt;90 percent of patients will also have granulomas [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">
          "Pulmonary complications of primary immunodeficiencies", section on 'Interstitial diseases'
         </a>
         .)
        </p>
        <p>
         Demonstration of the polyclonality of the infiltrates (usually B cells) distinguishes LIP from pulmonary lymphoma. T cell-predominant infiltrates have been reported in some patients with HIV, although no clear pattern of cell type is known [
         <a href="#rid1">
          1,15,25
         </a>
         ]. Mutations in the noncoding regulatory (promoter) regions of B cell lymphoma 6 (BCL-6) gene have been identified in several pulmonary lymphoproliferative disorders, including mucosa-associated lymphoid tissue (MALT) lymphoma, HIV-related, Epstein-Barr virus (EBV)-related, and virus-negative lymphocytic interstitial pneumonia (LIP) [
         <a href="#rid26">
          26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4703.html" rel="external">
          "Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma", section on 'Alterations in BCL6'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)"
         </a>
         .)
        </p>
        <p>
         It is particularly important to establish the benign nature of the lesion. Features suggesting malignant transformation include lymphangitic or bronchovascular distribution, monoclonality, hilar or pleural involvement, bronchial wall infiltration, and loss of germinal center architecture [
         <a href="#rid6">
          6,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fewer than 5 percent of patients are asymptomatic at presentation. Cough (71 percent of cases) and dyspnea (61 percent), slowly progressive over months and in rare cases several years (mean duration before diagnosis = 19 months), are the most common presenting symptoms of lymphoid interstitial pneumonia (LIP) [
         <a href="#rid3">
          3,6,9
         </a>
         ].
        </p>
        <p>
         Other symptoms and/or signs include as the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Weight loss (16 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fevers (10 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleuritic chest pain (6 percent)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fatigue
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arthralgias
        </p>
        <p>
        </p>
        <p>
         In a case series from an HIV endemic setting, 32 patients with definite or probable LIP were described [
         <a href="#rid28">
          28
         </a>
         ]. Definite LIP occurred most commonly (85 percent) in young women (median age 34 years) in the setting of a median CD4 count of 194 cell/mL. Among those with definite LIP, the predominant symptom was cough (90 percent), which was productive in 64 percent; mild to moderate dyspnea was present in 70 percent.
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Examination of the chest reveals crackles in most patients. Digital clubbing is seen in 10 percent of cases, and cyanosis is found rarely. Other findings often depend upon the presence of another underlying disease process (especially Sjögren's disease) and include hepatosplenomegaly, lymphadenopathy, parotid gland enlargement, and arthritis [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5593.html" rel="external">
          "Clinical manifestations of Sjögren’s disease: Extraglandular disease"
         </a>
         .)
        </p>
        <p>
         In the case series of 32 adults with HIV-associated definite or probable LIP mentioned above, approximately 60 percent had bibasilar crackles and 20 percent had clubbing [
         <a href="#rid28">
          28
         </a>
         ]. Other case reports have noted fever and weight loss [
         <a href="#rid2">
          2,19,29-31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H128054464">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The presence of lymphoid interstitial pneumonia (LIP) is usually suspected in the patient with an associated rheumatic disorder (eg, Sjögren's disease) and characteristic radiographic findings (see
         <a class="local">
          'Chest imaging'
         </a>
         below) [
         <a href="#rid32">
          32
         </a>
         ]. The evaluation of patients with LIP is similar to that of patients with other suspected interstitial lung diseases. Initial evaluation is focused on determining whether an underlying systemic process is the cause of the pulmonary abnormality. (See
         <a class="local">
          'Etiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/4310.html" rel="external">
          "Approach to the adult with interstitial lung disease: Clinical evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h2">
          Laboratory
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients without known rheumatic disease who present with new onset of ILD, the evaluation follows that of interstitial lung disease (ILD) in general and includes serologic testing (eg, antinuclear antibody, rheumatoid factor) and testing for HIV infection. Additional serologic tests are based upon the clinical features and results of initial testing. In patients with symptoms suggestive of Sjögren's disease, we also obtain anti-Ro/SSA and/or anti-La/SSB antibodies, quantitative immunoglobulin levels, and a serum protein electrophoresis. Similarly, if rheumatoid arthritis is suspected, anticyclic citrullinated antibodies are obtained. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Laboratory tests'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Laboratory'
         </a>
         .)
        </p>
        <p>
         In adults who are HIV positive, onset of LIP does not correlate with CD4 count, although LIP is more closely associated with immunodeficiency in children. (See
         <a class="medical medical_review" href="/z/d/html/5963.html" rel="external">
          "Pediatric HIV infection: Classification, clinical manifestations, and outcome"
         </a>
         .)
        </p>
        <p>
         The laboratory abnormalities in idiopathic LIP generally reflect the underlying disease state. Up to three-fourths of patients have a serum protein abnormality [
         <a href="#rid1">
          1,6
         </a>
         ]. The dysproteinemia is most commonly a polyclonal gammopathy, but occasionally can be a monoclonal gammopathy. In children, hypogammaglobulinemia may be identified [
         <a href="#rid6">
          6,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">
          "Pulmonary complications of primary immunodeficiencies", section on 'Interstitial diseases'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h2">
          Chest imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         LIP has a varied radiographic appearance [
         <a href="#rid34">
          34
         </a>
         ]; basilar reticular opacities or nodular densities may be seen on the chest radiograph. As the disease progresses, alveolar spaces become involved, and a mixed pattern of ground glass and consolidative opacities appears. Air bronchograms may be seen in larger, mass-like lesions. Nodular disease appears to be more common in patients with HIV [
         <a href="#rid5">
          5,8
         </a>
         ].
        </p>
        <p>
         High resolution computed tomography (HRCT) is useful to establish the extent and location of lung involvement, define the hilar anatomy, and identify any pleural involvement. Ground-glass attenuation, centrilobular nodules, and interstitial thickening are frequently seen with a lower lobe predominance [
         <a href="#rid24">
          24
         </a>
         ]. These findings are similar to those of nonspecific interstitial pneumonia (NSIP) [
         <a href="#rid24">
          24,35
         </a>
         ]. Lung cysts occur in 68 to 82 percent of patients with LIP  (
         <a class="graphic graphic_diagnosticimage graphicRef89082" href="/z/d/graphic/89082.html" rel="external">
          image 1
         </a>
         ), whereas they are rare in NSIP and pulmonary lymphoma, and can be helpful in distinguishing LIP from these entities [
         <a href="#rid10">
          10,24,36,37
         </a>
         ]. The cysts in LIP tend to be discrete and peribronchovascular in distribution [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         Pleural thickening and effusions are rare in LIP, as are hilar and mediastinal lymphadenopathy, so these findings suggest an underlying malignant process.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Pulmonary function tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete lung function testing (spirometry, lung volumes, diffusing capacity) and resting and exercise pulse oximetry are obtained in virtually all patients with suspected ILD.
        </p>
        <p>
         In patients with LIP, pulmonary function testing characteristically shows reduced lung volumes (eg, forced vital capacity [FVC], total lung capacity [TLC]) and diffusing capacity (DLCO) with preserved airflow. In one case series, the mean DLCO was 62 percent of predicted [
         <a href="#rid9">
          9
         </a>
         ]. Marked hypoxemia can also occur [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Pulmonary function testing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Bronchoalveolar lavage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bronchoalveolar lavage is typically performed in patients with ILD to exclude infection, certain occupational causes of ILD, chronic eosinophilic pneumonia, and malignancy. (See
         <a class="medical medical_review" href="/z/d/html/4358.html" rel="external">
          "Approach to the adult with interstitial lung disease: Diagnostic testing", section on 'Role of bronchoalveolar lavage'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease"
         </a>
         .)
        </p>
        <p>
         BAL is less helpful in securing a diagnosis of LIP, as the BAL findings are nonspecific. The total BAL cell count is increased compared with normal; a BAL lymphocytosis of approximately 30 percent has been reported [
         <a href="#rid9">
          9
         </a>
         ]. The proportion of B and T lymphocytes varies among studies [
         <a href="#rid9">
          9,32,39
         </a>
         ]. BAL lymphocytosis is also seen in hypersensitivity pneumonitis, sarcoidosis, and chronic beryllium disease. (See
         <a class="medical medical_review" href="/z/d/html/4308.html" rel="external">
          "Role of bronchoalveolar lavage in diagnosis of interstitial lung disease", section on 'Lymphocytic BAL'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1042443152">
         <span class="h2">
          Lung biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         As the clinical features, radiographic appearance, and BAL findings are not specific for LIP, a definitive diagnosis requires a surgical lung biopsy [
         <a href="#rid4">
          4,6
         </a>
         ]. Surgical lung biopsy via video-assisted thoracoscopic surgery (VATS) or thoracotomy is preferred over transbronchial biopsy as the small size of a transbronchial specimen is often insufficient for diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/4379.html" rel="external">
          "Role of lung biopsy in the diagnosis of interstitial lung disease", section on 'Specimen collection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of lymphoid interstitial pneumonia (LIP) is generally established by a lung biopsy that demonstrates extensive alveolar septal infiltration with lymphocytes, plasma cells, and histiocytes  (
         <a class="graphic graphic_table graphicRef69805" href="/z/d/graphic/69805.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid23">
          23
         </a>
         ]. Since LIP is a benign disorder, the lymphocytic infiltrate, usually B cells, must be polyclonal. (See
         <a class="local">
          'Pathologic findings'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/16921.html" rel="external">
          "Interpretation of lung biopsy results in interstitial lung disease", section on 'Lymphoid interstitial pneumonia'
         </a>
         .)
        </p>
        <p>
         An exception to the need for a lung biopsy is in HIV-positive children, as the clinical presentation and radiographic findings are considered sufficiently diagnostic to make a lung biopsy unnecessary.
        </p>
        <p>
         Once the diagnosis of LIP is ascertained, the specific cause or disease association should be identified  (
         <a class="graphic graphic_table graphicRef70714" href="/z/d/graphic/70714.html" rel="external">
          table 1
         </a>
         ). The patient’s medication list should be reviewed for use of
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         . Useful tests include the following (if not already performed):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis (SPEP)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum immunoglobulin (Ig)G4 level (consistent with IgG4-related disease if ≥2 times the upper limit of normal) (see
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         HIV-1/2 immunoassay (see
         <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">
          "Screening and diagnostic testing for HIV infection", section on 'Tests'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antinuclear antibody (ANA)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anti-Ro/SSA and anti-La/SSB antibodies (see
         <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">
          "Diagnosis and classification of Sjögren’s disease", section on 'Serologic and other laboratory testing'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rheumatoid factor
        </p>
        <p>
        </p>
        <p>
         Granulomatous and lymphocytic interstitial lung disease (GLILD) is characterized by granulomatous and lymphoproliferative (eg, lymphoid interstitial pneumonia [LIP], follicular bronchiolitis) histopathologic patterns in the lung in a patient with common variable immunodeficiency (CVID) or another primary immunodeficiency, such as hypomorphic mutations in recombination-activating gene 1 (RAG1), haploinsufficiency of cytotoxic T lymphocyte antigen-4 (CTLA4), and deficiency in lipopolysaccharide responsive beige-like anchor protein (LRBA). (See
         <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">
          "Pulmonary complications of primary immunodeficiencies", section on 'Interstitial diseases'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6381.html" rel="external">
          "Classification of diffuse lung disease (interstitial lung disease) in infants and children", section on 'Lymphoid interstitial pneumonia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of lymphoid interstitial pneumonia (LIP) includes: pseudolymphoma, lymphomatoid granulomatosis, follicular bronchiolitis, primary pulmonary lymphoma, bronchocentric granulomatosis, IgG4-related disease, and hypersensitivity pneumonitis (eg, characterized by the nonspecific interstitial pneumonia [NSIP] pattern). Plasma cell interstitial pneumonia and benign lymphocytic angiitis and granulomatosis are ill-defined and cannot be applied to any current entity; these terms are no longer used.
        </p>
        <p>
         Features that help distinguish these disorders from LIP include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A clinical setting of underlying rheumatic disease (particularly Sjögren's disease), common variable immunodeficiency, or HIV infection would favor LIP.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The presence of the following histologic findings is most consistent with an underlying lymphoma (eg, extranodal marginal zone lymphoma or small lymphocytic lymphoma): monoclonality, lymphangitic or bronchovascular distribution, hilar or pleural involvement, bronchial wall infiltration, and loss of germinal center architecture. Antibody panels can be used to differentiate lymphoma from LIP. (See
         <a class="medical medical_review" href="/z/d/html/4733.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)", section on 'Immunophenotype'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pulmonary amyloidosis (AL type) has been described in a case series of eight patients with primary Sjögren's disease who presented with cough and dyspnea [
         <a href="#rid40">
          40
         </a>
         ]. The main CT findings were cysts and multiple nodules; no patients had reticular opacities or septal thickening, or consolidation. All patients had anti-SS-A/Ro and anti-SS-B/La antibodies. Amyloid can be confirmed by Congo red staining (showing green birefringence under polarized light) and immunohistochemistry of lung biopsy samples. Three of these patients also had mucosa-associated lymphoid tissue (MALT) lymphoma. (See
         <a class="medical medical_review" href="/z/d/html/4301.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Clinical manifestations, evaluation, and diagnosis", section on 'Pulmonary nodular amyloidosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pathologic appearance of LIP and hypersensitivity pneumonitis is similar, although the latter tends to be more patchy [
         <a href="#rid2">
          2
         </a>
         ]. Hypersensitivity pneumonitis is more likely in patients with a history of exposure to agents known to be associated with the disorder, and findings on HRCT are usually upper and mid-lung zone predominant [
         <a href="#rid41">
          41
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4309.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Epidemiology, causes, and pathogenesis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Characteristic histologic patterns distinguish LIP from lymphomatoid granulomatosis and follicular bronchiolitis. (See
         <a class="medical medical_review" href="/z/d/html/4324.html" rel="external">
          "Pulmonary lymphomatoid granulomatosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4323.html" rel="external">
          "Overview of bronchiolar disorders in adults", section on 'Follicular bronchiolitis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IgG4-related disease is associated with a variety of patterns on HRCT rounded or diffuse ground-glass opacities and solid nodules [
         <a href="#rid42">
          42
         </a>
         ]. In addition, sicca symptoms can be seen with both Sjögren's disease and IgG4-related disease, thus making it important to exclude this diagnosis in patients with suspected LIP. In IgG4-related disease, the serum IgG4 level is elevated in approximately 85 percent of affected patients. Flow cytometry demonstrating elevation in blood plasmablasts is strongly suggestive of IgG4-related disease. The diagnosis is established by demonstration of IgG4 staining on histopathology. (See
         <a class="medical medical_review" href="/z/d/html/121220.html" rel="external">
          "Clinical manifestations and diagnosis of IgG4-related disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In HIV-infected patients, infectious etiologies of diffuse pulmonary opacities (eg,
         <em>
          Pneumocystis jirovecii
         </em>
         pneumonia [PCP], cytomegalovirus, and mycobacteria) must be excluded. (See
         <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">
          "Evaluation of pulmonary symptoms in persons with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">
          "Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5963.html" rel="external">
          "Pediatric HIV infection: Classification, clinical manifestations, and outcome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The differential diagnosis of granulomatous and lymphocytic interstitial lung disease (GLILD) includes sarcoidosis and hypersensitivity pneumonitis. However, sarcoidosis typically has normal or elevated serum immunoglobulin levels and may have a characteristic imaging pattern of bilateral symmetric hilar adenopathy which would not be typical of GLILD. Hypersensitivity pneumonitis is typically distinguished by the presence of normal immunoglobulin levels and a history of exposure to culprit antigens. (See
         <a class="medical medical_review" href="/z/d/html/4313.html" rel="external">
          "Hypersensitivity pneumonitis (extrinsic allergic alveolitis): Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">
          "Clinical manifestations and diagnosis of sarcoidosis", section on 'Diagnostic approach'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Controlled clinical trials have not been reported for lymphoid interstitial pneumonia (LIP). Information on treatment comes from case reports and case series. The treatment of LIP differs depending on the severity of the patient's symptoms, the degree of functional impairment, and the presence or absence of an associated rheumatic disease, immunodeficiency, or HIV infection.
        </p>
        <p class="headingAnchor" id="H344267220">
         <span class="h2">
          LIP in rheumatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         The treatment of patients with LIP complicating rheumatic disease (eg, Sjögren's disease, rheumatoid arthritis, systemic lupus erythematosus) is based on the severity of lung impairment, evidence of progression, and the treatment requirements of the underlying disease. Most patients with LIP associated with a rheumatic disease are symptomatic and have evidence of physiologic impairment. No clinical trials have been performed, but our experience suggests that such patients respond well to oral glucocorticoids, although some require an additional immunosuppressive agent.
        </p>
        <p>
         Some patients will require treatment for extrapulmonary manifestations of their rheumatic disease, which may also treat their lung disease. Detailed discussions of the management of patients with specific rheumatic diseases are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/15921.html" rel="external">
          "Interstitial lung disease associated with Sjögren's disease: Management and prognosis", section on 'Lymphoid interstitial pneumonia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7516.html" rel="external">
          "General principles and overview of management of rheumatoid arthritis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4362.html" rel="external">
          "Interstitial lung disease in rheumatoid arthritis", section on 'Treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4675.html" rel="external">
          "Overview of the management and prognosis of systemic lupus erythematosus in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4681.html" rel="external">
          "Pulmonary manifestations of systemic lupus erythematosus in adults", section on 'Interstitial lung disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/113735.html" rel="external">
          "Treatment of Sjögren's disease: Constitutional and non-sicca organ-based manifestations", section on 'Cardiopulmonary manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6400.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial regimen
         </strong>
         – For symptomatic patients with either physiologic impairment at presentation or deterioration in lung function over time, we suggest initiating systemic glucocorticoid therapy although data are insufficient to determine definitively whether treatment alters the natural history of the disease [
         <a href="#rid2">
          2,8,9
         </a>
         ]. We define physiologic impairment by a forced vital capacity (FVC) or diffusing capacity for carbon monoxide (DLCO) less than 70 percent of predicted and deterioration in function by a decrease in FVC or DLCO by 10 percent or more. In the largest reported series, 13 of 15 patients (three had idiopathic disease) were administered glucocorticoid therapy. Among the nine in whom the response could be evaluated, clinical improvement was noted in four, clinical stabilization in four, and disease progression in one. Median survival was approximately 12 years. Overall, about one-half appeared to respond with improvement or stabilization of disease [
         <a href="#rid8">
          8,9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our initial regimen is oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or the equivalent dose of
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         ) 0.25 to 0.5 mg/kg given once per day (based upon the patient's ideal body weight but not exceeding 60 mg/day). This dose is continued for 8 to 12 weeks, at which time the patient is reevaluated. The response to therapy is determined by improvement in symptoms, radiographic appearance (ie, high resolution computed tomography [HRCT]), and physiologic parameters (ie, FVC, total lung capacity [TLC], DLCO). If the patient's condition is stable or improved, the dose is tapered over 6 to 8 weeks to 0.25 mg/kg per day. Prednisone is maintained at that level for an additional 6 to 12 weeks, and then tapered further as tolerated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The proper length of therapy in patients who respond to treatment is not known. We usually aim for a treatment course of at least six months to one year; discontinuing treatment prematurely is a relatively frequent cause of relapse in patients who initially responded. Lifelong treatment with low dose therapy (less than 0.25 mg/kg per day) may be required by a small number of patients who respond to initial aggressive treatment. Alternate day oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         therapy is not recommended, since no data are available to suggest that it is effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest Pneumocystis prophylaxis for any patient with LIP receiving moderate to high dose glucocorticoid (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         20 mg or more per day). We recommend Pneumocystis prophylaxis for patients who are on a combination of high dose glucocorticoid and another immunosuppressive agent (see
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         ). Management of other complications of chronic systemic glucocorticoids is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2034.html" rel="external">
          "Prevention and treatment of glucocorticoid-induced osteoporosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Refractory disease
         </strong>
         – About 20 percent of patients have progressive disease despite systemic glucocorticoid therapy. For these patients and for those who experience side effects from the glucocorticoids, we add another immunosuppressive agent. There is no clear consensus on the optimal agent to choose. However, several case reports and small patient series (usually including patients with rheumatic disease and heterogeneous associated diagnoses) have reported some success with
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid2">
          2,9,43,44
         </a>
         ]. The use of these agents is described in the discussion of immunosuppressive therapy for nonspecific interstitial pneumonitis. (See
         <a class="medical medical_review" href="/z/d/html/4306.html" rel="external">
          "Treatment and prognosis of nonspecific interstitial pneumonia", section on 'Additional immunosuppressive drugs'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H344267381">
         <span class="h2">
          Idiopathic LIP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most reported patients with idiopathic LIP have had significant respiratory symptoms and/or physiologic impairment at the time of diagnosis and will require therapy. For the occasional patient with idiopathic LIP who has minimal symptoms and mild disease (based on physiologic and radiographic studies), we suggest careful longitudinal clinical, functional, and radiological evaluation before drug treatment [
         <a href="#rid2">
          2,9
         </a>
         ]. This approach is based on the observation that spontaneous remission is observed in a small percentage of such patients.
        </p>
        <p>
         For symptomatic patients with physiologic impairment at presentation or deterioration in lung function over time, we suggest initiating systemic glucocorticoid therapy based on the experience with LIP associated with rheumatic disease. Some patients will also need an additional immunosuppressive agent [
         <a href="#rid9">
          9,45
         </a>
         ]. (See
         <a class="local">
          'LIP in rheumatic disease'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          GLILD in common variable immunodeficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Granulomatous and lymphocytic interstitial lung disease (GLILD) in the setting of common variable immunodeficiency can lead to progressive pulmonary fibrosis and respiratory failure if untreated. However, GLILD is often poorly responsive to glucocorticoid treatment, and the optimal treatment is unknown. Small numbers of patients with GLILD have been treated successfully with tumor necrosis factor-alpha antagonists,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , or a combination of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and an antimetabolite (either
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         or
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ). The management of GLILD is discussed in more detail separately. (See
         <a class="local">
          'Immunodeficiency/dysregulation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/15830.html" rel="external">
          "Pulmonary complications of primary immunodeficiencies", section on 'Granulomatous and lymphocytic interstitial lung disease'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          LIP in HIV infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         The approach to the management of LIP in HIV-infected patients varies based upon the severity of disease and whether antiretroviral therapy (ART) is currently being administered.
        </p>
        <p>
         Among those who have not been previously treated with ART, we suggest initiating ART for symptomatic LIP, even though LIP is not technically an AIDS-defining illness [
         <a href="#rid46">
          46,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">
          "Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"
         </a>
         .) This is based on the following observations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several case reports and a case series have described improvement in LIP after initiation of ART [
         <a href="#rid19">
          19,47,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The overall incidence of LIP is decreasing, which is temporally associated with the introduction of ART [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         If ART therapy is not effective alone, the addition of glucocorticoids may be effective [
         <a href="#rid25">
          25,50,51
         </a>
         ]. We typically use the dosing regimen described above for LIP associated with rheumatic disease. However, the use of any agent that may lead to further immunosuppression in a compromised patient must be undertaken with caution and close surveillance.
        </p>
        <p>
         Among HIV infected patients who develop LIP or have progressive LIP despite being treated with ART, we assess whether the ART regimen is optimal and modify it, if necessary. If LIP progresses despite an optimal ART regimen, we suggest the addition of glucocorticoids based on personal experience and the response of HIV-infected patients with LIP to glucocorticoids in the pre-ART era [
         <a href="#rid31">
          31,52,53
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3766.html" rel="external">
          "Switching antiretroviral therapy for adults with HIV-1 and a suppressed viral load"
         </a>
         .)
        </p>
        <p>
         We suggest Pneumocystis prophylaxis in HIV-infected patients with LIP, who need high dose glucocorticoid therapy (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         20 mg or more per day), in addition to those who meet other criteria for Pneumocystis prophylaxis. (See
         <a class="local">
          'Idiopathic'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3709.html" rel="external">
          "Treatment and prevention of Pneumocystis infection in patients with HIV", section on 'Antimicrobial prophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history and prognosis of lymphoid interstitial pneumonia (LIP) are poorly understood. Possible outcomes include spontaneous resolution, stabilization of disease, resolution following treatment (eg, with glucocorticoids or other immunosuppressive agents), progression to lymphoma, or progression to pulmonary fibrosis with respiratory insufficiency and death despite glucocorticoid treatment [
         <a href="#rid1">
          1,2,6,8,9
         </a>
         ].
        </p>
        <p>
         Among 15 patients with LIP that was associated with rheumatic disease, idiopathic, or associated with hypogammaglobulinemia (but not HIV) who received no therapy, glucocorticoids, or glucocorticoids with other immunomodulatory therapy, the median survival was 11.5 years [
         <a href="#rid9">
          9
         </a>
         ]. Three patients progressed to end-stage lung disease; malignant transformation was not noted.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          LONG-TERM COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While approximately 5 percent of patients with LIP develop lymphoma and the risk of lymphoma is increased in patients with Sjögren's disease, it is unclear whether LIP undergoes malignant transformation or whether the lymphoma develops as a comorbid process [
         <a href="#rid2">
          2,54-57
         </a>
         ]. Lymphomas arising in association with LIP lesions are generally associated with prolonged survival, as they are typically well-differentiated and slow growing mucosa-associated lymphoid tissue (MALT) lymphomas [
         <a href="#rid11">
          11,56
         </a>
         ].
        </p>
        <p>
         Secondary infections are a serious and potentially fatal complication of the primary immunologic abnormality (eg, HIV, hypogammaglobulinemia) or as a complication of immunosuppressive therapy [
         <a href="#rid8">
          8,9,33
         </a>
         ]. Infections with both typical and atypical organisms occur.
        </p>
        <p class="headingAnchor" id="H2010246284">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/118793.html" rel="external">
          "Society guideline links: Interstitial lung disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lymphoid interstitial pneumonia (LIP) is characterized by infiltration of the interstitium and alveolar spaces of the lung by lymphocytes, plasma cells, and other lymphoreticular elements. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LIP represents a benign polyclonal proliferation (usually of mature B or T cells) that can involve the lung diffusely, or be a focal process. Germinal centers, noncaseating granulomas, and multinucleated giant cells may also be seen. (See
         <a class="local">
          'Classification'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         As the disease progresses, fibrotic and cystic changes are seen along with loss of lung parenchyma. (See
         <a class="local">
          'Pathologic findings'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The specific etiology of LIP is unknown: its association with autoimmune diseases (eg, Sjögren's disease, systemic lupus erythematosus) suggests an autoimmune etiology and its association with HIV infection suggests a possible viral infectious etiology. (See
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical manifestations include cough, dyspnea, and less commonly, weight loss and fever. Lung examination reveals crackles. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         On high resolution chest CT, ground-glass attenuation, centrilobular nodules (single or multiple) or masses, mixed ground glass-consolidative opacities, and septal thickening are typical  (
         <a class="graphic graphic_diagnosticimage graphicRef89082" href="/z/d/graphic/89082.html" rel="external">
          image 1
         </a>
         ). Lung cysts are also common, especially in HIV-associated LIP. (See
         <a class="local">
          'Chest imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Open or thoracoscopic lung biopsy is often
         <strong>
          required
         </strong>
         to confirm the diagnosis, as biopsy specimens need to be large enough for the pathologist to define architectural elements and test for clonality. Imaging alone is sufficient in HIV-positive children. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with idiopathic or rheumatic disease-associated LIP who are asymptomatic and have mild disease (based on physiologic and radiographic studies), we suggest not initiating treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We follow these patients with longitudinal assessment of clinical, functional, and radiological parameters. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In adults with LIP associated with rheumatic disease who are symptomatic, have significant physiologic impairment, or who demonstrate progressive disease on longitudinal assessments, we suggest treatment with oral glucocorticoids (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We typically initiate oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         (or the equivalent dose of
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         ) 0.25 to 0.5 mg/kg given once a day (based upon the patient's ideal body weight but not exceeding 60 mg/day). The course of therapy is usually 6 to 12 months. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with idiopathic LIP, we typically follow the regimen outlined for LIP in rheumatic disease. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with idiopathic LIP, who do not respond to, or are intolerant of glucocorticoid therapy, we suggest adding an additional immunosuppressive agent (eg,
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         ) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest Pneumocystis prophylaxis for any patient with LIP receiving moderate to high dose glucocorticoid (eg,
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         20 mg or more per day) (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We also suggest Pneumocystis prophylaxis in patients treated with a combination of glucocorticoid and another immunosuppressive agent (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV", section on 'Prophylaxis'
         </a>
         ). We follow current treatment recommendations for prevention of other potential adverse effects of glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">
          "Major adverse effects of systemic glucocorticoids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In HIV-infected patients (including children) with symptomatic LIP and no other indication for antiretroviral therapy (ART), we suggest initiating ART (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We suggest not initiating glucocorticoid therapy until after a trial of optimal ART (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). For patients whose LIP progresses despite optimal ART, we follow the treatment protocol for glucocorticoid therapy outlined for LIP in rheumatic disease. (See
         <a class="local">
          'Treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignant transformation of LIP to lymphoma may infrequently occur years after the initial diagnosis. Lymphomas arising from LIP lesions are associated with prolonged survival, as they are well differentiated and slow growing. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Koss MN, Hochholzer L, Langloss JM, et al. Lymphoid interstitial pneumonia: clinicopathological and immunopathological findings in 18 cases. Pathology 1987; 19:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swigris JJ, Berry GJ, Raffin TA, Kuschner WG. Lymphoid interstitial pneumonia: a narrative review. Chest 2002; 122:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carrington, BC, Liebow, AA. Lymphocytic interstitial pneumonia (abstract). Am J Pathol 1966; 48:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188:733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bragg DG, Chor PJ, Murray KA, Kjeldsberg CR. Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features. AJR Am J Roentgenol 1994; 163:273.
          </a>
         </li>
         <li class="breakAll">
          Cosgrove GP, Schwartz MI. Lymphocytoplasmic infiltrations of the lung. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People's Medical Publishing House, Shelton, CT, USA 2011. p.1045.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alkhayer M, McCann BG, Harrison BD. Lymphocytic interstitial pneumonitis in association with Sjogren's syndrome. Br J Dis Chest 1988; 82:305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strimlan CV, Rosenow EC 3rd, Weiland LH, Brown LR. Lymphocytic interstitial pneumonitis. Review of 13 cases. Ann Intern Med 1978; 88:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cha SI, Fessler MB, Cool CD, et al. Lymphoid interstitial pneumonia: clinical features, associations and prognosis. Eur Respir J 2006; 28:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rajagopala S, Swamy S, Kumar A, Rout P. Ace in the hole! Respiration 2011; 82:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta N, Vassallo R, Wikenheiser-Brokamp KA, McCormack FX. Diffuse Cystic Lung Disease. Part II. Am J Respir Crit Care Med 2015; 192:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao N, Mackinnon AC, Routes JM. Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency--histologic and immunohistochemical analyses of 16 cases. Hum Pathol 2015; 46:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubinstein A, Morecki R, Silverman B, et al. Pulmonary disease in children with acquired immune deficiency syndrome and AIDS-related complex. J Pediatr 1986; 108:498.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi VV, Oleske JM, Minnefor AB, et al. Pathologic pulmonary findings in children with the acquired immunodeficiency syndrome: a study of ten cases. Hum Pathol 1985; 16:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Travis WD, Fox CH, Devaney KO, et al. Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus nonspecific interstitial pneumonitis. Hum Pathol 1992; 23:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghrenassia E, Martis N, Boyer J, et al. The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review. J Autoimmun 2015; 59:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setoguchi Y, Takahashi S, Nukiwa T, Kira S. Detection of human T-cell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia. Am Rev Respir Dis 1991; 144:1361.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Principi N, Marchisio P, Massironi E, et al. Effect of zidovudine in HIV-infected children with lymphocytic interstitial pneumonitis. AIDS 1991; 5:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dufour V, Wislez M, Bergot E, et al. Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy. Clin Infect Dis 2003; 36:e127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barberà JA, Hayashi S, Hegele RG, Hogg JC. Detection of Epstein-Barr virus in lymphocytic interstitial pneumonia by in situ hybridization. Am Rev Respir Dis 1992; 145:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz BZ, Berkman AB, Shapiro ED. Serologic evidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome. J Pediatr 1992; 120:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer MR, Saldana MJ, Ramos M, Pitchenik AE. High titers of Epstein-Barr virus antibodies in adult patients with lymphocytic interstitial pneumonitis associated with AIDS. Respir Med 1992; 86:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johkoh T, Fukuoka J, Tanaka T. Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs. Eur J Radiol 2015; 84:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin RY, Gruber PJ, Saunders R, Perla EN. Lymphocytic interstitial pneumonitis in adult HIV infection. N Y State J Med 1988; 88:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurosu K, Weiden MD, Takiguchi Y, et al. BCL-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia. J Immunol 2004; 172:7116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Turner RR, Colby TV, Doggett RS. Well-differentiated lymphocytic lymphoma. A study of 47 patients with primary manifestation in the lung. Cancer 1984; 54:2088.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Zyl-Smit RN, Naidoo J, Wainwright H, et al. HIV associated Lymphocytic Interstitial Pneumonia: a clinical, histological and radiographic study from an HIV endemic resource-poor setting. BMC Pulm Med 2015; 15:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris JC, Rosen MJ, Marchevsky A, Teirstein AS. Lymphocytic interstitial pneumonia in patients at risk for the acquired immune deficiency syndrome. Chest 1987; 91:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ripamonti D, Rizzi M, Maggiolo F, et al. Resolution of lymphocytic interstitial pneumonia in a human immunodeficiency virus-infected adult following the start of highly active antiretroviral therapy. Scand J Infect Dis 2003; 35:348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saito M, Hatakeyama S, Wakabayashi Y, et al. A pathologically proven case of adult-onset HIV-related lymphocytic interstitial pneumonia with acute exacerbation treated with steroid and antiretroviral therapy. J Infect Chemother 2015; 21:868.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panchabhai TS, Farver C, Highland KB. Lymphocytic Interstitial Pneumonia. Clin Chest Med 2016; 37:463.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Popa V. Lymphocytic interstitial pneumonia of common variable immunodeficiency. Ann Allergy 1988; 60:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hare SS, Souza CA, Bain G, et al. The radiological spectrum of pulmonary lymphoproliferative disease. Br J Radiol 2012; 85:848.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johkoh T, Müller NL, Pickford HA, et al. Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients. Radiology 1999; 212:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ichikawa Y, Kinoshita M, Koga T, et al. Lung cyst formation in lymphocytic interstitial pneumonia: CT features. J Comput Assist Tomogr 1994; 18:745.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honda O, Johkoh T, Ichikado K, et al. Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT. AJR Am J Roentgenol 1999; 173:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sverzellati N, Lynch DA, Hansell DM, et al. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002. Radiographics 2015; 35:1849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishizaki T, Miyabo S, Koshino T, et al. Lymphoid interstitial pneumonia: findings at bronchoalveolar lavage. Eur J Respir Dis 1985; 67:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baqir M, Kluka EM, Aubry MC, et al. Amyloid-associated cystic lung disease in primary Sjögren's syndrome. Respir Med 2013; 107:616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silva CI, Churg A, Müller NL. Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings. AJR Am J Roentgenol 2007; 188:334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bois MC, Sekiguchi H, Ryu JH, Yi ES. No definite clinical features of immunoglobulin G4-related disease in patients with pulmonary nodular lymphoid hyperplasia. Hum Pathol 2017; 59:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008; 68:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010; 304:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen B, Li HP, Zhang RX, et al. [Idiopathic lymphoid interstitial pneumonia: a report of 3 cases and literature review]. Zhonghua Nei Ke Za Zhi 2008; 47:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Das S, Miller RF. Lymphocytic interstitial pneumonitis in HIV infected adults. Sex Transm Infect 2003; 79:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Innes AL, Huang L, Nishimura SL. Resolution of lymphocytic interstitial pneumonitis in an HIV infected adult after treatment with HAART. Sex Transm Infect 2004; 80:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarborough M, Lishman S, Shaw P, et al. Lymphocytic interstitial pneumonitis in an HIV-infected adult: response to antiretroviral therapy. Int J STD AIDS 2000; 11:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kourtis AP, Bansil P, Posner SF, et al. Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample. Pediatrics 2007; 120:e236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ingiliz P, Appenrodt B, Gruenhage F, et al. Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation. HIV Med 2006; 7:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kazi S, Cohen PR, Williams F, et al. The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients. AIDS 1996; 10:385.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teirstein AS, Rosen MJ. Lymphocytic interstitial pneumonia. Clin Chest Med 1988; 9:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffiths MH, Miller RF, Semple SJ. Interstitial pneumonitis in patients infected with the human immunodeficiency virus. Thorax 1995; 50:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banerjee D, Ahmad D. Malignant lymphoma complicating lymphocytic interstitial pneumonia: a monoclonal B-cell neoplasm arising in a polyclonal lymphoproliferative disorder. Hum Pathol 1982; 13:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuurman HJ, Gooszen HC, Tan IW, et al. Low-grade lymphoma of immature T-cell phenotype in a case of lymphocytic interstitial pneumonia and Sjögren's syndrome. Histopathology 1987; 11:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatron PY, Tillie-Leblond I, Launay D, et al. Pulmonary manifestations of Sjögren's syndrome. Presse Med 2011; 40:e49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishback N, Koss M. Update on lymphoid interstitial pneumonitis. Curr Opin Pulm Med 1996; 2:429.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4361 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3453998" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lymphoid interstitial pneumonia: clinicopathological and immunopathological findings in 18 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12475860" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lymphoid interstitial pneumonia: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Lymphocytic interstitial pneumonia (abstract)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24032382" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037014" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8037014" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Lymphoproliferative disorders of the lung: histopathology, clinical manifestations, and imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3248213" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Lymphocytic interstitial pneumonitis in association with Sjogren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/646244" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Lymphocytic interstitial pneumonitis. Review of 13 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16571614" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Lymphoid interstitial pneumonia: clinical features, associations and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21576925" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Ace in the hole!
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25906201" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Diffuse Cystic Lung Disease. Part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26138782" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Granulomatous and lymphocytic interstitial lung disease: a spectrum of pulmonary histopathologic lesions in common variable immunodeficiency--histologic and immunohistochemical analyses of 16 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3007714" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pulmonary disease in children with acquired immune deficiency syndrome and AIDS-related complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3972404" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Pathologic pulmonary findings in children with the acquired immunodeficiency syndrome: a study of ten cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1314778" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lymphoid pneumonitis in 50 adult patients infected with the human immunodeficiency virus: lymphocytic interstitial pneumonitis versus nonspecific interstitial pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25660200" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The diffuse infiltrative lymphocytosis syndrome (DILS). A comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1741550" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Detection of human T-cell lymphotropic virus type I-related antibodies in patients with lymphocytic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2059391" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effect of zidovudine in HIV-infected children with lymphocytic interstitial pneumonitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12746792" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Improvement of symptomatic human immunodeficiency virus-related lymphoid interstitial pneumonia in patients receiving highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1313215" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Detection of Epstein-Barr virus in lymphocytic interstitial pneumonia by in situ hybridization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1310507" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Serologic evidence of active Epstein-Barr virus infection in Epstein-Barr virus-associated lymphoproliferative disorders of children with acquired immunodeficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1314403" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : High titers of Epstein-Barr virus antibodies in adult patients with lymphocytic interstitial pneumonitis associated with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11790668" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25591580" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Rare idiopathic intestinal pneumonias (IIPs) and histologic patterns in new ATS/ERS multidisciplinary classification of the IIPs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3288914" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Lymphocytic interstitial pneumonitis in adult HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15153535" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : BCL-6 mutations in pulmonary lymphoproliferative disorders: demonstration of an aberrant immunological reaction in HIV-related lymphoid interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6386139" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Well-differentiated lymphocytic lymphoma. A study of 47 patients with primary manifestation in the lung.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25896166" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : HIV associated Lymphocytic Interstitial Pneumonia: a clinical, histological and radiographic study from an HIV endemic resource-poor setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3491742" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lymphocytic interstitial pneumonia in patients at risk for the acquired immune deficiency syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12875528" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Resolution of lymphocytic interstitial pneumonia in a human immunodeficiency virus-infected adult following the start of highly active antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26298039" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : A pathologically proven case of adult-onset HIV-related lymphocytic interstitial pneumonia with acute exacerbation treated with steroid and antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27514593" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lymphocytic Interstitial Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3348496" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Lymphocytic interstitial pneumonia of common variable immunodeficiency.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22745203" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The radiological spectrum of pulmonary lymphoproliferative disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10429719" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Lymphocytic interstitial pneumonia: thin-section CT findings in 22 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8089323" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Lung cyst formation in lymphocytic interstitial pneumonia: CT features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10397102" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Differential diagnosis of lymphocytic interstitial pneumonia and malignant lymphoma on high-resolution CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26452110" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3876947" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lymphoid interstitial pneumonia: findings at bronchoalveolar lavage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23402779" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Amyloid-associated cystic lung disease in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17242239" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27720730" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : No definite clinical features of immunoglobulin G4-related disease in patients with pulmonary nodular lymphoid hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19000095" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Anti-CD20 treatment in primary Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20664046" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of primary Sjögren syndrome: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19040067" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : [Idiopathic lymphoid interstitial pneumonia: a report of 3 cases and literature review].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12690125" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lymphocytic interstitial pneumonitis in HIV infected adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15459417" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Resolution of lymphocytic interstitial pneumonitis in an HIV infected adult after treatment with HAART.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10678481" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Lymphocytic interstitial pneumonitis in an HIV-infected adult: response to antiretroviral therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17606535" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Trends in hospitalizations of HIV-infected children and adolescents in the United States: analysis of data from the 1994-2003 Nationwide Inpatient Sample.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16903987" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8728042" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The diffuse infiltrative lymphocytosis syndrome. Clinical and immunogenetic features in 35 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3044682" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Lymphocytic interstitial pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8553268" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Interstitial pneumonitis in patients infected with the human immunodeficiency virus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7106742" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Malignant lymphoma complicating lymphocytic interstitial pneumonia: a monoclonal B-cell neoplasm arising in a polyclonal lymphoproliferative disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3500906" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Low-grade lymphoma of immature T-cell phenotype in a case of lymphocytic interstitial pneumonia and Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21194883" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pulmonary manifestations of Sjögren's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9363179" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Update on lymphoid interstitial pneumonitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
